APLM

Apollomics Inc. operates as a clinical-stage biopharmaceutical company focused on developing oncology therapies through a platform of combination-based treatments. Headquartered in Foster City, California, the company targets cancer through its proprietary approach of combining multiple anti-cancer agents to overcome resistance mechanisms and improve patient outcomes. Apollomics advances a pipeline of novel drug candidates, with its lead asset being vebreltinib (APL-101), an orally administered c-Met inhibitor in clinical trials for non-small cell lung cancer and other solid tumors. The company also develops APL-501, a bispecific antibody targeting CD3 and CD20 for hematologic malignancies, and maintains a portfolio of additional oncology candidates at various development stages. Apollomics operates through a strategic business model that emphasizes both in-house development and partnerships for its combination therapy platform. In recent developments, the company has focused on advancing clinical trials across its pipeline while pursuing regulatory pathways in both U.S. and international markets. The firm trades publicly on the Nasdaq under the ticker symbol APLM following its business combination with Maxpro Capital Acquisition Corp in 2022. Apollomics maintains research collaborations with academic institutions and pharmaceutical partners to expand its oncology platform and accelerate clinical development of its investigational therapies.